Key corporate developments have been announced across the Hong Kong market. Bao Pharma-B (HKEX: 02659) reported that the clinical trial application for its BJ044 injection (recombinant ulinastatin) has received approval from the National Medical Products Administration.
FIBOCOM (HKEX: 00638) plans to acquire a 37.16% stake in Hangsheng Electronics for approximately RMB 1.428 billion, aiming to achieve vertical integration of "communication modules + automotive electronic systems" through both hardware and software.
ENVISION GREEN (HKEX: 01783) has proposed an acquisition of up to HKD 2.5 billion for the entire equity of YV CLOUD Limited and Shanghai Youfuyun, marking a strategic move into the IDC and AI computing power business sectors.
MINIEYE (HKEX: 02431) announced the completion of registration for its joint venture focused on full-scenario physical AI.
IDT International (HKEX: 00167) has seen a change in its controlling interest, with a mandatory unconditional cash offer made at a discount of approximately 91.51%. Trading in its shares is set to resume on June 30.
Kuanyi International (HKEX: 01683) has entered into a strategic cooperation framework agreement with an artificial intelligence development group to jointly establish a global OPC ecosystem alliance for global entrepreneurs.
China Wantian Holdings (HKEX: 01854) disclosed that its subsidiary has signed a strategic cooperation framework agreement with Zhongyi Embodied Intelligence for a proposed partnership in the field of robotic products and AIoT solutions.
PegBio Co., Ltd.-B (HKEX: 02565) announced that its core product, Vipeptide Injection, has passed the preliminary formal review for the 2026 National Reimbursement Drug List adjustment.
Braincare-B (HKEX: 06681) was awarded the championship in the 2026 Xiong'an International Medical and Health Technology Application Competition and also released several significant recent scientific research achievements.
Financial Performance Updates
YIDU TECH (HKEX: 02158) released its annual results, reporting a profit attributable to shareholders of RMB 72.709 million. This marks a historic milestone for the company, successfully transitioning from a loss-making position to profitability.
Huake Intelligent Investment (HKEX: 01140) announced its annual performance, with profit attributable to owners reaching HKD 6.172 billion, representing a substantial increase of 9519.74% year-on-year.
Hui Han Holdings (HKEX: 00214) published its annual results, showing a loss attributable to shareholders of HKD 1.088 billion. This figure represents a 51% narrowing of the loss compared to the previous year.
Fanhaitat Group (HKEX: 00129) reported its annual performance, with a loss attributable to shareholders of HKD 1.861 billion, a 50% reduction from the prior year.
EC Healthcare (HKEX: 02138) disclosed its annual results, indicating a loss attributable to equity holders of approximately HKD 403 million, which grew by about 141% year-on-year.
Victory City International Holdings (HKEX: 02199) announced its annual performance, with profit attributable to owners of approximately HKD 283 million, a 53.9% increase compared to the previous year.
Tsugami Precision Engineering (China) (HKEX: 01651) released its annual results, showing a profit attributable to shareholders of RMB 1.094 billion, up 39.87% year-on-year.
China Water Affairs Group (HKEX: 00855) published its annual performance, reporting a profit attributable to shareholders of HKD 986 million, an 8.2% decrease from the prior year.